Industry: Health care Region: Belgium Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A Belgian company, founded in 2022, focuses on continuous innovation in the health field and specializes in equipment development. Liquid biopsy technology, which is dedicated to cancer prognosis and personalized medicine, has now expanded its platform beyond the field of cancer, providing a one-stop solution for various analysis and biological applications. The company's unique internal whole-process processing mode only needs the customer to define the problem clearly.
Introduction to core technologies:
The company is developing a new generation of label-free flow cytometry, which is similar to traditional flow cytometry, but based on electrical impedance cytometry. This method does not use biomarkers and lasers, but simultaneously applies low AC voltage signals with different frequencies. Each compartment in a cell has specific electrical characteristics, and this technology can identify these characteristics. Microfluidic device technology can run at very high frequency, so it can measure the changes of biophysical properties of the whole cell. Users can easily make unmarked measurements and generate rich data with various application values, from size measurement to cell cycle monitoring. The collected data is easy to access, and users can visit these data at any time to explore different cell characteristics.
Cooperation mode:
Seek partners interested in unlabeled and non-invasive cell analysis equipment and technology in China.